TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02573714
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
Study: NCT00928447
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20
Study: NCT00928447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mL ID syringe push bolus injection of placebo control
Study: NCT03356457
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Placebo oral capsule identical in shape and color to those with active ingredient.
Study: NCT01588496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT02238522
Drug: ZEN003365
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00861523
Drug: thiamine & promethazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: thiamine 100 mg IV promethazine 25 mg IV
Study: NCT02739295
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002565
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002565
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002565
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01327547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
Study: NCT00208923
Drug: Busulfan, Cyclophosphamide and Fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.~* Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.~* Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days.
Study: NCT03975166
Drug: Test Product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations in one study period
Study: NCT04041310
Drug: KEYTRUDA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 checkpoint inhibitor (200 mg; Q3W)
Study: NCT00885118
Drug: Placebo (middle dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once a day
Study: NCT00885118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once a day
Study: NCT00885118
Drug: Placebo (high dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once a day
Study: NCT03975166
Drug: Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations in one study period
Study: NCT01535950
Drug: LFG316
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01535950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.
Study: NCT00885118
Drug: Placebo (low dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once a day
Study: NCT01990326
Drug: XAF5 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01990326
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00795613
Drug: CONVENTIONAL ABVD
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
Study: NCT02105623
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Risk factor control rosuvastatin 5mg/day for 24months
Study: NCT01511627
Drug: General Anesthesia + Spinal anesthesia combined
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Patients will receive a spinal anesthetic with:~* Bupivacaine 0.5% 10 mg~* Fentanyl 10ug~* Epidural Morphine 150ug~After the spinal, a general anesthetic will be induced using:~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously Patients will receive a Morphine PCA to be initiated in the Post Anesthetic Care Unit (PACU).
Study: NCT01511627
Drug: General Anesthesia (control group)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Group I (General anesthetic) patients will receive a general anesthetic :~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg. to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously~Patients will receive a Morphine PCA as per protocol that will be initiated in the Post Anesthetic Care Unit (PACU).
Study: NCT02575859
Drug: adjuvant HIPEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
Study: NCT00067509
Drug: emergency contraception (estrogen/progesterone)
Normalized name: Emergency contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00511901
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01558011
Drug: Capecitabine, Oxaliplatin, Docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.~Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy.
Study: NCT02976701
Drug: DLBS1033
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02976701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02976701
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.
Study: NCT04780347
Drug: Albumin-bound paclitaxel plus capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin-bound paclitaxel plus capecitabine: Albumin-bound paclitaxel 260mg/m2, IV , D1, q3w； capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
Study: NCT04780347
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine: capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
Study: NCT02631447
Drug: LGX818
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGX818 450 mg p.o. od
Study: NCT02631447
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK162 45 mg p.o. bid
Study: NCT02106767
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20mg po x1
Study: NCT02106767
Drug: Rosuvastatin plus rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1
Study: NCT01747161
Drug: Botulin toxin
Normalized name: Botulin toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 I.E. Botulin toxin. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
Study: NCT00413972
Drug: ezetimibe with simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
Study: NCT00413972
Drug: Ezetimibe with Simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
Study: NCT00413972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for a total of eight weeks
Study: NCT01759407
Drug: Ropivicaine
Normalized name: Ropivicaine-Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01759407
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04018599
Drug: 40 mg MSB11022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
Study: NCT02354768
Drug: Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone
Normalized name: loperamide hydrochloride Oral Tablet [Maalox Anti-Diarrheal]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03749356
Drug: TacroBell SR cap.
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment.
Study: NCT01070030
Drug: Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were asked for 2 week run-in phase with atenolol 50 mg qd(once a day), followed by 4 schedule visits with 4-week interval until patient achieved BP goal. The maximum follow up was 16-week treatment. At visit 2, the patients started receiving Aliskiren/Amlodipine (150/5mg per day) for 4 weeks. At visit 3, if the patients did not achieve blood pressure (BP) goal, patients were up titrated to Aliskiren/Amlodipine (300/10 mg/day) for 4 weeks. At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks. Finally at visit 5, if the patients did not achieve BP goal, HCT was up titrated to Aliskiren/Amlodipine/HCT (300/10/25 mg/day) for 4 weeks until visit 6. Once the patients achieved BP goal at any visit, they completed the study.
Study: NCT02331251
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00956748
Drug: Ciprodex and 2% NAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
Study: NCT01848951
Drug: Epidural
Normalized name: Epidural 17g 3.5"
Approvals — FDA: no, EMA: no, PMDA: no
Description: The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed. Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain institution's standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
Study: NCT00790322
Drug: SBG
Normalized name: PSBG - Pregnancy specific beta 1-glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble beta-1,3/1,6-glucan is a solution for oral use
Study: NCT01700504
Drug: Axillary lavage with gentamicin solution
Normalized name: gentamicin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
Study: NCT02728518
Drug: Nebulized Amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg twice daily nebulized amikacin
Study: NCT02728518
Drug: Intravenous Amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg/kg once daily intravenous amikacin
Study: NCT00379249
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03330119
Drug: Alternate Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: With the alternate management protocol, the pre-operative order set is the same, with the addition of a single preoperative dose of acetaminophen 1 g IV x1, gabapentin 600 mg PO x1, and ondansetron 8 mg IV x1. Post-operatively, patients receive the same ketorolac 30mg x 9 doses every 6 hours, as well as acetaminophen 975 mg every 6 hours, both given standing. These two are timed so the patient is receiving one of the two medications every 3 hours during their inpatient stay. After 9 doses of ketorolac, the patient receives 600mg of ibuprofen PO, also given standing, instead of the ketorolac. If the patient requires narcotics, they may receive them on an as needed basis. IV fluids are running at 80 cc/ hour. Patients are encouraged to ambulate, including the evening of the surgery, have their foley catheter removed 12 hours post-operatively, and can have a regular diet immediately.
Study: NCT02593500
Drug: Budesonida Pulmictan® 200 µg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01244009
Drug: MK-4827
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
Study: NCT00114556
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04720443
Drug: NIP292 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIP292 (oral tablet at 10 mg) or placebo
Study: NCT04720443
Drug: NIP292 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIP292 (oral tablet at 30 mg) or placebo
Study: NCT04720443
Drug: NIP292 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIP292 (oral tablet at 100 mg) or placebo
Study: NCT04720443
Drug: NIP292 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIP292 (oral tablet at 300 mg) or placebo
Study: NCT01491529
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.~Patients will be randomized in two groups by amantadine status.~* Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~* Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)
Study: NCT01491529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for AFQ056 will be supplied as oral tablets.
Study: NCT04720443
Drug: NIP292 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIP292 (oral tablet at 500 mg) or placebo
Study: NCT04720443
Drug: NIP292 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIP292 (oral tablet at dosage 1) or placebo
Study: NCT04720443
Drug: NIP292 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIP292 (oral tablet at dosage 2) or placebo
Study: NCT03318744
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo resembling aspirin tablet will be be given to participants in control arm.
Study: NCT01548404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection altered between back of arms, abdomen and upper thighs.
Study: NCT00002331
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02396043
Drug: induction phase1
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8,22
Study: NCT02396043
Drug: induction phase2
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide: 1000 mg/m2 iv on days 35, 59,Cytarabine: 75 mg/m2 iv on days 35-38, 42-45, 49-52, 56-59,Mercaptopurine: 60 mg/m2 po on days 35-59
Study: NCT02396043
Drug: maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase
Study: NCT02396043
Drug: reinduction phase1
Normalized name: REDUCTIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8
Study: NCT02396043
Drug: reinduction phase2
Normalized name: REDUCTIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42
Study: NCT04461483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-935 placebo-matching tablets
Study: NCT00649662
Drug: Cipro® XR Tablets 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg, single dose fasting
Study: NCT01294423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for Dapagliflozin 5mg/10mg oral dose
Study: NCT00861978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
Study: NCT02070133
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg once a day during 12 weeks
Study: NCT02070133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once a day during 12 weeks
Study: NCT04027920
Drug: Shenghua Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three days' shenghua decoction treatment
Study: NCT01521949
Drug: Acai Juice Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ounces of Acai Juice Product twice daily.
Study: NCT00002521
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02401360
Drug: China Crest® Pro-health 7 Complete Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
Study: NCT02401360
Drug: China Crest® Cavity Protection Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crest® meliliangje manual toothbrush
Study: NCT04635839
Drug: Standard Dose of Unfractionated Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 units subcutaneous unfractionated heparin every 12 hours
Study: NCT04121195
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
Study: NCT00435591
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampoule or premix bag
Study: NCT04635839
Drug: Gestational Age-Based Dose of Unfractionated Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: * First trimester (\< 14 weeks of gestation): 5,000 units subcutaneous unfractionated heparin every 12 hours~* Second trimester (14-28 weeks of gestation): 7,500 units subcutaneous unfractionated heparin every 12 hours~* Third trimester (\> 28 weeks of gestation): 10,000 units subcutaneous unfractionated heparin every 12 hours
Study: NCT00210470
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single i.v. injection of low-dose (300 mg/m2) on Day 1
Study: NCT00210470
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 days of oral indomethacin, 25 mg. 3 times daily
Study: NCT00210470
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 21 days of zinc gluconate (65 mg) as part of an oral multivitamin
Study: NCT01008293
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
Study: NCT03279263
Drug: MLR-1023
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLR-1023 Tablets